{"entity":{"id":"nct06064812","kind":"trial","name":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","aka":[],"tldr":"A phase 1/2 trial of FWD1802 in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.","summary":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. is a phase 1/2 interventional study registered as NCT06064812 by Forward Pharmaceuticals Co., Ltd., with 99 participants planned, started 2023-09-12 and due to reach its primary completion in 2026-03. Interventions recorded: FWD1802.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06064812","url":"https://clinicaltrials.gov/study/NCT06064812"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["forward-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06064812","phase":"1/2","setting":"A Phase I/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of FWD1802in Patients With ER+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer","sponsor":"Forward Pharmaceuticals Co., Ltd.","enrolled":99,"outcomes":[]},"route":"/trials/nct06064812/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/"}]}}